ATE443702T1 - Substituierte morpholin and thiomorpholin derivate - Google Patents

Substituierte morpholin and thiomorpholin derivate

Info

Publication number
ATE443702T1
ATE443702T1 AT08007169T AT08007169T ATE443702T1 AT E443702 T1 ATE443702 T1 AT E443702T1 AT 08007169 T AT08007169 T AT 08007169T AT 08007169 T AT08007169 T AT 08007169T AT E443702 T1 ATE443702 T1 AT E443702T1
Authority
AT
Austria
Prior art keywords
substituted morpholine
thiomorpholine derivatives
thiomorpholine
derivatives
morpholine
Prior art date
Application number
AT08007169T
Other languages
English (en)
Inventor
Thornoe Christian Wenzel
Mario Rottlaender
Nikolay Khanzhin
Andreas Ritzen
William Patrick Watson
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37730781&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE443702(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Application granted granted Critical
Publication of ATE443702T1 publication Critical patent/ATE443702T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/041,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/061,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/301,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D279/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/101,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/121,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
AT08007169T 2004-03-12 2005-03-09 Substituierte morpholin and thiomorpholin derivate ATE443702T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55257404P 2004-03-12 2004-03-12
DKPA200400412 2004-03-12

Publications (1)

Publication Number Publication Date
ATE443702T1 true ATE443702T1 (de) 2009-10-15

Family

ID=37730781

Family Applications (2)

Application Number Title Priority Date Filing Date
AT08007169T ATE443702T1 (de) 2004-03-12 2005-03-09 Substituierte morpholin and thiomorpholin derivate
AT05706819T ATE398112T1 (de) 2004-03-12 2005-03-09 Substituierte morpholin- und thiomorpholinderivate

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT05706819T ATE398112T1 (de) 2004-03-12 2005-03-09 Substituierte morpholin- und thiomorpholinderivate

Country Status (32)

Country Link
US (6) US7501414B2 (de)
EP (3) EP1947093B9 (de)
JP (1) JP5006184B2 (de)
KR (2) KR101411204B1 (de)
CN (2) CN102516204B (de)
AR (1) AR049784A1 (de)
AT (2) ATE443702T1 (de)
AU (1) AU2005221762B2 (de)
BR (1) BRPI0508570B8 (de)
CA (1) CA2559397C (de)
CO (1) CO5721001A2 (de)
CY (2) CY1110392T1 (de)
DE (2) DE602005007474D1 (de)
DK (2) DK1947093T3 (de)
EA (1) EA015120B1 (de)
EG (1) EG25344A (de)
ES (2) ES2334076T3 (de)
HK (1) HK1172618A1 (de)
HR (1) HRP20090685T1 (de)
IL (1) IL177859A (de)
MY (2) MY143698A (de)
NO (1) NO337161B1 (de)
NZ (1) NZ549133A (de)
PL (2) PL1947093T3 (de)
PT (2) PT1947093E (de)
RS (2) RS50606B (de)
SG (1) SG151254A1 (de)
SI (2) SI1727809T1 (de)
TW (2) TWI349666B (de)
UA (2) UA102517C2 (de)
WO (1) WO2005087754A1 (de)
ZA (2) ZA200607286B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050089559A1 (en) 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
TWI349666B (en) * 2004-03-12 2011-10-01 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivatives
UA89503C2 (uk) * 2004-09-13 2010-02-10 Х. Луннбек А/С Заміщені похідні аніліну
UA92340C2 (en) * 2005-03-03 2010-10-25 Х. Луннбек А/С Substituted pyridine derivatives
US7812020B2 (en) * 2005-03-03 2010-10-12 H. Lundbeck A/S Substituted pyridine derivatives
MX2008009655A (es) * 2006-02-07 2008-09-03 Lundbeck & Co As H Metodo para tratar o reducir los sintomas de la esquizofrenia.
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US8993593B2 (en) 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
AU2007288253B2 (en) 2006-08-23 2013-05-02 Xenon Pharmaceuticals Inc. Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
KR20090083479A (ko) 2006-11-28 2009-08-03 밸리언트 파마슈티컬즈 인터내셔널 칼륨 채널 조절제로서의 1,4 디아미노 이환 레티가빈 유사체
WO2008130616A2 (en) * 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines as cb1 modulators
US8367684B2 (en) 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US20100256145A1 (en) * 2007-08-01 2010-10-07 H. Lundbeck A/S Use of kcnq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted
US7786146B2 (en) 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
EP2116618A1 (de) 2008-05-09 2009-11-11 Agency for Science, Technology And Research Diagnose und Behandlung des Kawasaki-Syndroms
WO2010094644A1 (en) * 2009-02-17 2010-08-26 Neurosearch A/S Substituted pyridine derivatives and their medical use
WO2010094645A1 (en) * 2009-02-17 2010-08-26 Neurosearch A/S Substituted pyridine derivatives and their medical use
TW201041857A (en) * 2009-05-11 2010-12-01 Lundbeck & Co As H Stable forms of N-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide
US20100286138A1 (en) * 2009-05-11 2010-11-11 H. Lundbeck A/S Stable forms of N-(2,6-Dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide
WO2011026891A1 (en) * 2009-09-07 2011-03-10 Neurosearch A/S Substituted pyridine derivatives and their medical use
AU2011275393B2 (en) 2010-07-08 2014-04-10 Pfizer Inc. Piperidinyl pyrimidine amides as Kv7 potassium channel openers
CN103073455B (zh) 2011-10-25 2015-08-19 中国科学院上海药物研究所 一类新型的kcnq钾通道激动剂、其制备方法和用途
US9321750B2 (en) * 2012-04-20 2016-04-26 Innov17 Llc ROR modulators and their uses
CN103044431A (zh) * 2012-10-22 2013-04-17 中国药科大学 制备五氟磺草胺的新方法
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US20170360726A1 (en) * 2014-12-05 2017-12-21 Aquinnah Pharmaceuticals, Inc. Compounds, compositions and methods of use
EP3366683A1 (de) * 2017-02-28 2018-08-29 Acousia Therapeutics GmbH Zyklische amide, acetamide und harnstoffe als kalium kanal öffner
WO2020157126A1 (en) 2019-01-29 2020-08-06 Università degli Studi di Salerno Modulators of potassium ion channels and uses thereof
IL282188A (en) * 2021-04-08 2022-11-01 Yeda Res & Dev Combined use of ketamine and bretigabine for the treatment of psychiatric disorders

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03175086A (ja) * 1989-09-14 1991-07-30 Fuji Photo Film Co Ltd ジアゾ感熱記録材料
DE4200259A1 (de) 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
DE19539861A1 (de) 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
NZ329200A (en) * 1996-12-16 1999-05-28 Hoechst Ag Sulphonamide substituted quinazoline, isoquinoline, quinoline or benzo[1,3-]oxazine derivatives and medicaments
US6187797B1 (en) * 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
WO1998028282A2 (en) 1996-12-23 1998-07-02 Du Pont Pharmaceuticals Company OXYGEN OR SULFUR CONTAINING 5-MEMBERED HETEROAROMATICS AS FACTOR Xa INHIBITORS
EA003056B1 (ru) * 1996-12-23 2002-12-26 Дюпон Фармасьютикалз Компани АЗОТСОДЕРЖАЩИЕ ГЕТЕРОАРОМАТИЧЕСКИЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА Ха, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ
BR9813835A (pt) 1997-12-22 2000-10-10 Du Pont Pharm Co Composto, composição farmacêutica e método de tratamento ou prevenção de uma desordem tromboembólica
JP2002509924A (ja) * 1998-03-27 2002-04-02 デュポン ファーマシューティカルズ カンパニー 第Xa因子阻害剤としてのジ置換ピラゾリン類およびトリアゾリン類
US6495550B2 (en) * 1999-08-04 2002-12-17 Icagen, Inc. Pyridine-substituted benzanilides as potassium ion channel openers
AU772075B2 (en) * 1999-08-04 2004-04-08 Icagen, Inc. Methods for treating or preventing pain and anxiety
US6117900A (en) 1999-09-27 2000-09-12 Asta Medica Aktiengesellschaft Use of retigabine for the treatment of neuropathic pain
IL152202A0 (en) 2000-05-26 2003-05-29 Bristol Myers Squibb Co Human kcnq5 polypeptide and pharmaceutical compositions containing the same
WO2001096540A2 (en) 2000-06-11 2001-12-20 Dupont Pharmaceuticals Company Hepatitis c protease exosite for inhibitor design
PE20020044A1 (es) * 2000-06-16 2002-01-30 Upjohn Co Tiazina oxazolidinona
US6589986B2 (en) * 2000-12-20 2003-07-08 Wyeth Methods of treating anxiety disorders
EP1353915A2 (de) * 2001-01-16 2003-10-22 AstraZeneca AB Therapeutische chromanverbindungen
JP2004517129A (ja) * 2001-01-16 2004-06-10 アストラゼネカ・アクチエボラーグ 治療用クロモン化合物
CN1250519C (zh) * 2001-01-19 2006-04-12 中国人民解放军军事医学科学院毒物药物研究所 具有调节钾通道功能的胺衍生物及其制备方法和应用
JP2005508833A (ja) * 2001-02-20 2005-04-07 ブリストル−マイヤーズ スクイブ カンパニー Kcnqカリウムチャネル・モジュレーターとしての2,4−ジ置換ピリミジン−5−カルボキサミド誘導体
SE0103649D0 (sv) * 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinoline compounds
SE0103648D0 (sv) * 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinolone compounds
TWI349666B (en) 2004-03-12 2011-10-01 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivatives

Also Published As

Publication number Publication date
IL177859A (en) 2013-02-28
HK1172618A1 (zh) 2013-04-26
ES2306087T3 (es) 2008-11-01
CY1110392T1 (el) 2015-04-29
US20100063033A1 (en) 2010-03-11
ATE398112T1 (de) 2008-07-15
PL1947093T3 (pl) 2010-02-26
IL177859A0 (en) 2006-12-31
CN102516204B (zh) 2016-01-20
EG25344A (en) 2011-12-14
DE602005016849D1 (de) 2009-11-05
NZ549133A (en) 2010-09-30
JP2007528880A (ja) 2007-10-18
CO5721001A2 (es) 2007-01-31
US20090137571A1 (en) 2009-05-28
AU2005221762B2 (en) 2011-06-09
CN1930138A (zh) 2007-03-14
US20090143369A1 (en) 2009-06-04
UA102517C2 (ru) 2013-07-25
RS50606B (sr) 2010-05-07
AU2005221762A1 (en) 2005-09-22
ZA200607286B (en) 2008-04-30
ES2334076T3 (es) 2010-03-04
NO337161B1 (no) 2016-02-01
EP1947093A1 (de) 2008-07-23
US7812023B2 (en) 2010-10-12
CA2559397A1 (en) 2005-09-22
CY1109656T1 (el) 2014-08-13
US8299075B2 (en) 2012-10-30
EP1947093B1 (de) 2009-09-23
PT1947093E (pt) 2009-12-22
RS51066B (sr) 2010-10-31
TW200533359A (en) 2005-10-16
CN102516204A (zh) 2012-06-27
KR20120136422A (ko) 2012-12-18
DK1727809T3 (da) 2008-09-29
SI1947093T1 (sl) 2010-01-29
TWI357901B (en) 2012-02-11
PT1727809E (pt) 2008-08-13
JP5006184B2 (ja) 2012-08-22
CA2559397C (en) 2010-08-10
MY143698A (en) 2011-06-30
EA200601686A1 (ru) 2007-02-27
AR049784A1 (es) 2006-09-06
EP2138487A1 (de) 2009-12-30
US20110294787A1 (en) 2011-12-01
KR101411204B1 (ko) 2014-06-23
SI1727809T1 (sl) 2008-10-31
EP1727809B1 (de) 2008-06-11
NO20064599L (no) 2006-12-08
ZA200709718B (en) 2008-09-25
EP1947093B9 (de) 2010-03-03
EP1727809B8 (de) 2008-10-29
DE602005007474D1 (en) 2008-07-24
US7632835B2 (en) 2009-12-15
BRPI0508570A (pt) 2007-08-14
PL1727809T3 (pl) 2008-11-28
MY147786A (en) 2013-01-31
WO2005087754A1 (en) 2005-09-22
DK1947093T3 (da) 2010-02-01
KR20060128004A (ko) 2006-12-13
BRPI0508570B8 (pt) 2021-05-25
US20100063036A1 (en) 2010-03-11
US8012962B2 (en) 2011-09-06
BRPI0508570B1 (pt) 2018-11-21
US20060167248A1 (en) 2006-07-27
TW200811121A (en) 2008-03-01
UA90670C2 (en) 2010-05-25
EP1727809A1 (de) 2006-12-06
HRP20090685T1 (hr) 2010-02-28
TWI349666B (en) 2011-10-01
US7501414B2 (en) 2009-03-10
SG151254A1 (en) 2009-04-30
EA015120B1 (ru) 2011-06-30

Similar Documents

Publication Publication Date Title
ATE443702T1 (de) Substituierte morpholin and thiomorpholin derivate
CY2015036I1 (el) Νεα παραγωγα οξαζολιδινονης
IS8152A (is) Tálmar fosfatídýlínósítól 3-kínasa
NL1030486A1 (nl) Dibenzylamineverbindingen en derivaten.
IS8578A (is) 3- karbamoýl - 2- pýridón afleiður
ATE383361T1 (de) Pyrrazolopyrimidinderivate
ATE540935T1 (de) Chinazolinderivate
ATE394399T1 (de) Tetrahydropyridoindolderivate
IS2656B (is) Nýjar besímídasólafleiður
DK1594840T3 (da) Piperidin-benzensulfonamid-derivater
ATE417830T1 (de) Sulfonylbenzimidazolderivate
ATE352550T1 (de) Chinazolinderivate
ATE430142T1 (de) Phenylpiperazin-methanon-derivate
ATE404542T1 (de) 4-phenylpyrimidin-2-carbonitrilderivate
DE50308254D1 (de) Messgerät
DK1682129T3 (da) N-thiazol-2-ylbenzamidderivater
DK1740574T3 (da) 4-amino-5-cyanopyrimidinderivater
NO20054552D0 (no) Peleanker med utvendige skovler
DE502005008147D1 (de) Funktion
ATE449064T1 (de) Amidoacetonitrilderivate
ATE369347T1 (de) Trimere makrocyclisch substituierte halogen- benzolderivate
DE10349030B4 (de) Axialverstellvorrichtung
SE0401972D0 (sv) Piperazine derivatives
ES1055831Y (es) Sabana bajera ajustable.
ITBS20040107A1 (it) Supporto registrabile

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1947093

Country of ref document: EP